X Bioscience PCL (BKK:XBIO)
Thailand · Delayed Price · Currency is THB 0.0700
0.00 (0.00%)
At close: Mar 27, 2026
X Bioscience PCL Cash Flow Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -468.87 | -260.22 | -147.52 | -575.99 | -276.45 |
Depreciation & Amortization | 36.94 | 65.35 | 46.04 | 143.95 | 118.78 |
Other Amortization | 3.12 | 1.94 | 0.57 | 2.27 | 1.28 |
Loss (Gain) From Sale of Assets | 169.44 | 0.59 | 0 | 98.28 | 0.26 |
Asset Writedown & Restructuring Costs | 109.81 | 99.32 | 25.06 | 86.78 | 4.52 |
Loss (Gain) From Sale of Investments | 15.25 | - | - | - | - |
Provision & Write-off of Bad Debts | - | 6.99 | - | - | - |
Other Operating Activities | 46.72 | 7.9 | 8.22 | 10.3 | 190.49 |
Change in Accounts Receivable | -0.95 | 21.17 | -3.12 | -9.72 | -10.28 |
Change in Inventory | 3.87 | -4.5 | 6.33 | -6.61 | -14.88 |
Change in Accounts Payable | -4.3 | 38.31 | -3.82 | 100.5 | 35.27 |
Change in Other Net Operating Assets | 13.67 | 4.64 | -8.06 | -2.16 | -11.58 |
Operating Cash Flow | -75.29 | -18.51 | -76.31 | -152.41 | -139.13 |
Capital Expenditures | -3.59 | -36.33 | -57.28 | -138.81 | -73.43 |
Sale of Property, Plant & Equipment | 1.41 | 2.11 | 4.1 | 3.51 | 0.06 |
Cash Acquisitions | - | -445.01 | - | - | - |
Divestitures | 14.79 | - | - | 267.06 | - |
Other Investing Activities | -0.12 | -0.19 | - | -0.2 | -0.6 |
Investing Cash Flow | 12.49 | -479.41 | -53.18 | 131.56 | -73.97 |
Short-Term Debt Issued | 53.07 | 28.06 | 260.5 | 517.45 | 294.59 |
Long-Term Debt Issued | - | - | - | - | 6 |
Total Debt Issued | 53.07 | 28.06 | 260.5 | 517.45 | 300.59 |
Short-Term Debt Repaid | -122.69 | -76.9 | -311.26 | -456.22 | -66.49 |
Long-Term Debt Repaid | -31 | -42.64 | -36.93 | -59.14 | -36.49 |
Total Debt Repaid | -153.69 | -119.54 | -348.19 | -515.36 | -102.97 |
Net Debt Issued (Repaid) | -100.62 | -91.48 | -87.69 | 2.09 | 197.61 |
Issuance of Common Stock | 171.96 | 590.84 | 227.78 | - | 0 |
Other Financing Activities | -16.16 | -18.99 | - | 6.9 | - |
Financing Cash Flow | 55.18 | 480.37 | 140.09 | 8.99 | 197.61 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 0.09 |
Net Cash Flow | -7.62 | -17.56 | 10.59 | -11.86 | -15.4 |
Free Cash Flow | -78.88 | -54.84 | -133.59 | -291.22 | -212.57 |
Free Cash Flow Margin | -60.84% | -17.18% | -42.85% | -84.54% | -83.67% |
Free Cash Flow Per Share | -0.20 | -0.30 | -1.07 | -2.50 | -1.83 |
Cash Interest Paid | 16.16 | 18.99 | 30.47 | 48.17 | 3.55 |
Levered Free Cash Flow | -532.87 | -109.31 | -99.45 | -202.98 | -1.21 |
Unlevered Free Cash Flow | -516.48 | -87.88 | -74.48 | -167.66 | 7.82 |
Change in Working Capital | 12.29 | 59.61 | -8.67 | 82.01 | -1.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.